Loehrer [23] PAC (c i s p l a t i n 5 0 m g /m 2 , d1; a d r i a my c i n 5 0 m g /m 2 , d1;
cyclophosphamide 500 mg/m 2 , d1; q3 weeks) 30 50 3.2
Fornasiero [24] ADOC (cisplatin 50 mg/m 2 , d1; adriamycin 40 mg/m 2 , d1; vincristine 0.6 mg/m 2 , d3; cyclophosphamide 700 mg/m 2 , d4; q4 weeks) 32 92 1.25
Giacone [25] PE (cisplatin 60 mg/m 2 , d1; etoposide 120 mg/m 2 , d1-d3; q3 weeks) 16 56 4.3
Loehrer [26] VIP (etoposide 75 mg/m 2 , d1-d4; ifosfamide 1.2 g/m 2 , d1-d4; cisplatin 20 mg/m 2 , d1-d4; q3 weeks) 28 32 2.7
Lemma [27] PC (paclitaxel 225 mg/m 2 , carboplatin AUC 5, q3 weeks) 24 33 >5
Yokoi [28] CAMP (cisplatin 20 mg/m 2 , d1-d4; adriamycin 40 mg/m 2 , d1; Koizumi [29] ADOC (cisplatin 50 mg/m 2 , d1; adriamycin 40 mg/m 2 , d1; vincristine 0.6 mg/m 2 , d3; cyclophosphamide 700 mg/m 2 , d4; q3-4 weeks) 8 75 1.6
Yoh [30] CODE (cisplatin 25 mg/m 2 , weekly; vincristine 1 mg/m 2 , weeks 1, 2, 4, 6, 8; doxorubicin 40 mg/m 2 , weeks 1, 3, 5, 7, 9; etoposide 80 mg/ m 2 , for 3 days during weeks 1, 3, 5, 7, 9) 12 42 3.8
Maruyama [31] PC (paclitaxel 200 mg/m 2 , carboplatin AUC6, q3 weeks) 6 100 NR Lemma [27] PC (paclitaxel 225 mg/m 2 , carboplatin AUC5, q3 weeks) 21 24
1.25
Lgawa [32] PC (paclitaxel 200 mg/m 2 , carboplatin AUC6, q3 weeks) 11 
